ClinicalTrials.gg
RecruitingNCT05516472FMT INDUpdated Oct 27, 2026

Fecal Microbiota Transplantation in Kidney Stone Patients

An Early Phase 1 interventional study of Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101) and Vancomycin and neomycin antibiotic pretreatment in Kidney Stones, Urinary Stone Disease / Nephrolithiasis and Recurrent Calcium-oxalate Kidney Stones, sponsored by Joshua Stern. Recruiting at 1 site in United States. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Joshua Stern · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 27, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.

Planned enrollment
116th of 165
20 · median 47
Started
2024
with 12 others
Phase 1
8 of 193
5 open now
Primary completion
2027-12
later than 38 of 57 live
Registered
138th of 193
by date

Among the 193 studies in Kidney Calculi with a site in United States, this one is the 116th largest by planned enrollment of the 165 interventional ones that give a count, is one of 13 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 38 of the 57 other live ones, and was the 138th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Kidney Calculi with a site in United States, or all of them as a file.
02

Study summary

This open-label pilot study evaluates whether oral microbial transplant therapy can change urine factors associated with recurrent calcium-oxalate kidney stones. Adults with high urine calcium or high urine oxalate will receive antibiotic pretreatment followed by microbial capsules. Changes in 24-hour urine calcium and oxalate and treatment safety will be assessed.

Read the detailed description

Participants with recurrent calcium-oxalate stones are assigned to a hyperoxaluric or hypercalciuric cohort based on baseline 24-hour urine results. All participants receive vancomycin 500 mg twice daily and neomycin 1,000 mg twice daily for 3 days. Forty-eight to 72 hours later, they take 2 microbial transplant therapy capsules daily for 7 days. Urine and stool samples are collected at baseline, after antibiotics, and during follow-up. Participants serve as their own controls. Follow-up includes weekly contacts through Week 5, telephone/record review at Months 2-6, and record review at Months 9 and 12

03

Conditions studied

  • Kidney Stones
  • Urinary Stone Disease / Nephrolithiasis
  • Recurrent Calcium-oxalate Kidney Stones

Keywords

  • microbial transplant therapy
  • kidney stones
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older and younger than 70 years.
  • Recent urinary stone disease with at least 50% calcium-oxalate composition confirmed by stone analysis.
  • 24-hour urinary calcium >225 mg/day or urinary oxalate >40 mg/day.
  • Able to provide .
  • Willing to complete safety follow-up, study visits, 24-hour urine collections, and serial stool collections.
  • Not actively participating in another interventional urinary stone disease trial.
  • >=60.

Exclusion criteria

Exclusion Criteria:

  • Three or more NIH-defined metabolic syndrome features.
  • Any disease or inflammatory bowel disease.
  • Major gastrointestinal surgery within 3 months, excluding appendectomy or cholecystectomy; history of total colectomy or bariatric surgery.
  • Primary or secondary hyperparathyroidism or PTH outside 15-65 pg/mL.
  • Pancreatic enzyme replacement, ongoing dialysis, or \<60.
  • Chemotherapy in the prior year or concurrent intensive cancer therapy.
  • Antibiotics within 3 months of study entry, continued antibiotic need, or anticipated antibiotic use in the next 4 weeks.
  • Unable to complete required from potassium citrate, thiazides, or proton pump inhibitors.
  • Pregnant, breastfeeding, or planning pregnancy during the study.
  • Unable or unwilling to swallow capsules, including grade >=2 dysphagia.
  • Active gastrointestinal infection, toxic megacolon, or small bowel ileus.
  • \<6 months.
  • Prior FMT or microbiome-based product outside this study.
  • Severe anaphylactic or anaphylactoid food allergy.
  • Solid organ transplant recipient.
  • Any condition jeopardizing safety or rights, preventing completion, or confounding results.
  • Urinary oxalate >=80 mg/day.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Hyperoxaluric group

    Participants with urinary oxalate \>40 mg/day and \<80 mg/day receive antibiotic pretreatment followed by MTT, 2 capsules daily for 7 days.

    Drug: Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101) · Drug: Vancomycin and neomycin antibiotic pretreatment

  • Experimental
    Hypercalciuric Group

    Participants with urinary calcium \>225 mg/day receive antibiotic pretreatment followed by MTT, 2 capsules daily for 7 days

    Drug: Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101) · Drug: Vancomycin and neomycin antibiotic pretreatment

Interventions

  • DrugMicrobial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101)

    Two capsules orally once daily for 7 days, beginning 48-72 hours after completion of antibiotic pretreatment.

    Also known as: fecal transplant

  • DrugVancomycin and neomycin antibiotic pretreatment

    Vancomycin 500 mg orally twice daily and neomycin 1,000 mg orally twice daily for 3 days before MTT.

06

What researchers measure

Primary outcomes

  1. Change in 24-hour urinary oxalate concentration from baseline

    Within-participant change in urinary oxalate concentration measured in 24-hour urine collections.

    Time frame: Baseline to Weeks 1, 3, and 5

  2. Change in 24-hour urinary calcium concentration from baseline

    Within-participant change in urinary calcium concentration measured in 24-hour urine collections.

    Time frame: Baseline to weeks 1, 3, and 5

  3. Proportion of participants with an adverse event

    Safety assessed as the proportion of participants experiencing an adverse event through the specified follow-up period.

    Time frame: Through Day 30 (+/- 3 days) after MTT

Secondary outcomes

  1. Metagenomic changes in participant microbiota before and after MTT

    Changes in stool microbiota measured by metagenomic analysis.

    Time frame: Baseline/pre-intervention through Week 5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Dec 2027, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Dec 2027 and completion Mar 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 25, 2022
StartActual
Oct 10, 2024
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Mar 2028was Mar 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2027
Oct 27, 2026
Study completion
Mar 2027→Mar 2028
Oct 27, 2026
Enrollment
36→20
Oct 27, 2026
Eligibility
4 inclusion criteria edited, 3 added, 4 removed; 8 exclusion criteria edited, 9 added, 22 removed
What changed in the criteria
Inclusion criteria
  • RemovedWomen and men age greater than or equal to 18 and less than 70
  • RemovedRecent medical history of USD with greater than or equal to 50% calcium-oxalate stones. All patients will have urinary stone disease confirmed by stone analysis. The study will include patients with either stones extracted by urological intervention or spontaneously passed and collected stones.
  • AddedAge 18 years or older and younger than 70 years.
  • AddedRecent urinary stone disease with at least 50% calcium-oxalate composition confirmed by stone analysis.
  • Edited24-hour urinary calcium concentration greater than >225 mg/day or urinary oxalate greater than >40 mg/day.
  • EditedAble to giveprovide informed consent.
  • RemovedWilling to undergo telephone follow-up to assess for safety and adverse events
  • EditedWilling and able to participate in the study requirementscomplete safety follow-up, including study visits, 24-hour urine collectioncollections, and serial stool collectioncollections.
  • EditedNot actively participating in another interventional USD clinicalurinary stone disease trial.
  • RemovedEstimated Glomerular Filtration Rate (eGFR) greater than or equal to 60.
  • AddedeGFR >=60.
Exclusion criteria
  • RemovedPresence of three features of metabolic syndrome as defined by the NIH to have 3 or more of the following conditions:
  • RemovedLarge waist - A waistline that measures at least 35 inches (89 centimeters) for women and 40 inches (102 centimeters) for men
  • RemovedHigh triglyceride level - 150 milligrams per deciliter (mg/dL), or 1.7 millimoles per liter (mmol/L), or higher of this type of fat found in blood
  • RemovedReduced good or HDL cholesterol - Less than 40 mg/dL (1.04 mmol/L) in men or less than 50 mg/dL (1.3 mmol/L) in women of high-density lipoprotein (HDL) cholesterol
  • RemovedIncreased blood pressure - 130/85 millimeters of mercury (mm Hg) or higher
  • RemovedElevated fasting blood sugar - 100 mg/dL (5.6 mmol/L) or higher
  • RemovedPresence of features of autoimmunity
  • RemovedMajor gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy
  • RemovedDiagnosis of inflammatory bowel disease
  • RemovedPatient diagnosed with primary hyperparathyroidism. Any patient with a PTH outside the range of 15 - 65 pg/ml will be excluded.
  • AddedThree or more NIH-defined metabolic syndrome features.
  • AddedAny autoimmune disease or inflammatory bowel disease.
  • EditedHistoryMajor gastrointestinal surgery within 3 months, excluding appendectomy or cholecystectomy; history of total colectomy or bariatric surgery.
  • RemovedConcurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy
  • EditedPatient diagnosedPrimary or secondary hyperparathyroidism. Any patient with a or PTH outside the range of 15 - 65 pg/ml will be excludedmL.
  • RemovedAll patients requiring pancreatic enzyme replacement will be excluded.
  • RemovedPatient with ongoing dialysis treatment
  • RemovedReceived chemotherapy treatment in the last 1 year
  • RemovedTreatment with antibiotics within 3 months of study entry. If subjects need to take antibiotics unexpectedly during the trial, they are excluded if they have already taken the fecal material transplant; if not, they can re-enroll in 3 months.
  • AddedPancreatic enzyme replacement, ongoing dialysis, or eGFR <60.
  • AddedChemotherapy in the prior year or concurrent intensive cancer therapy.
  • EditedRequiresAntibiotics within 3 months of study entry, continued antibiotic useneed, or anticipatesanticipated antibiotic use in the upcomingnext 4 weeks.
  • EditedPatients takingUnable to complete required washout from potassium citrate, thiazides, or proton pump inhibitors in the last 6 months.
  • RemovedWomen who are pregnant or breast-feeding or planning to get pregnant during the time of the study.
  • RemovedInability (e.g. dysphagia) to or unwilling to swallow capsules. Subjects with Grade greater than or equal to 2 dysphagia- as per Current Terminology for Common Adverse Events (CTCAE v 5.0) will be excluded.
  • RemovedActive gastrointestinal infection at time of enrollment
  • AddedPregnant, breastfeeding, or planning pregnancy during the study.
  • AddedUnable or unwilling to swallow capsules, including CTCAE grade >=2 dysphagia.
  • EditedKnown or suspectedActive gastrointestinal infection, toxic megacolon and/, or known small bowel ileus.

…and 10 more changes, on the record history on ClinicalTrials.gov ↗

Oct 27, 2026
Interventions
Changed Microbial Transplant Therapy→Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101). Added Drug: Vancomycin and neomycin antibiotic pretreatment; removed Drug: Placebo. Arms removed: Control group Hyperoxaluria·Control group Hypercalciuria
Oct 27, 2026
Primary outcomes
2 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedChangesChange in 24 -hour urinary oxalate concentration from baselineTime frame: Baseline to weeks 1, 3, and 5 → Baseline to Weeks 1, 3, and 5
  • EditedChangesChange in 24 -hour urinary calcium concentration from baselineTime frame: Baseline to week 1, 3, and 5 → Baseline to weeks 1, 3, and 5
  • Time frameProportion of participants with an adverse eventBaseline to day 30 (plus or minus 3 days) after fecal transplant → Through Day 30 (+/- 3 days) after MTT
  • DescriptionProportion of participants with an adverse event: how it is measured was reworded
Oct 27, 2026
Secondary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedMetagenomic changes in participant microbiota before and after MTTTime frame: Baseline/pre-intervention through Week 5
  • RemovedMetagenomic changes to subject microbiota pre-MTTTime frame: Prior to fecal transplant (baseline)
  • RemovedMetagenomic changes to subject microbiota post-MTTTime frame: weeks 4 and 5 after MTT
Oct 27, 2026
Contact
Study contact changed: d•••@imail.org · •••9421→n•••@imail.org · •••8280. See the current contact
Oct 27, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Park City Hospital · Park City, United StatesContact D•••@imail.org · •••9421→A•••@imail.org · •••9415
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Dec 2026→Dec 2027
    Study completion Mar 2027→Mar 2028
    Enrollment 36→20
    Eligibility 4 inclusion criteria edited, 3 added, 4 removed; 8 exclusion criteria edited, 9 added, 22 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedWomen and men age greater than or equal to 18 and less than 70
    • RemovedRecent medical history of USD with greater than or equal to 50% calcium-oxalate stones. All patients will have urinary stone disease confirmed by stone analysis. The study will include patients with either stones extracted by urological intervention or spontaneously passed and collected stones.
    • AddedAge 18 years or older and younger than 70 years.
    • AddedRecent urinary stone disease with at least 50% calcium-oxalate composition confirmed by stone analysis.
    • Edited24-hour urinary calcium concentration greater than >225 mg/day or urinary oxalate greater than >40 mg/day.
    • EditedAble to giveprovide informed consent.
    • RemovedWilling to undergo telephone follow-up to assess for safety and adverse events
    • EditedWilling and able to participate in the study requirementscomplete safety follow-up, including study visits, 24-hour urine collectioncollections, and serial stool collectioncollections.
    • EditedNot actively participating in another interventional USD clinicalurinary stone disease trial.
    • RemovedEstimated Glomerular Filtration Rate (eGFR) greater than or equal to 60.
    • AddedeGFR >=60.
    Exclusion criteria
    • RemovedPresence of three features of metabolic syndrome as defined by the NIH to have 3 or more of the following conditions:
    • RemovedLarge waist - A waistline that measures at least 35 inches (89 centimeters) for women and 40 inches (102 centimeters) for men
    • RemovedHigh triglyceride level - 150 milligrams per deciliter (mg/dL), or 1.7 millimoles per liter (mmol/L), or higher of this type of fat found in blood
    • RemovedReduced good or HDL cholesterol - Less than 40 mg/dL (1.04 mmol/L) in men or less than 50 mg/dL (1.3 mmol/L) in women of high-density lipoprotein (HDL) cholesterol
    • RemovedIncreased blood pressure - 130/85 millimeters of mercury (mm Hg) or higher
    • RemovedElevated fasting blood sugar - 100 mg/dL (5.6 mmol/L) or higher
    • RemovedPresence of features of autoimmunity
    • RemovedMajor gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy
    • RemovedDiagnosis of inflammatory bowel disease
    • RemovedPatient diagnosed with primary hyperparathyroidism. Any patient with a PTH outside the range of 15 - 65 pg/ml will be excluded.
    • AddedThree or more NIH-defined metabolic syndrome features.
    • AddedAny autoimmune disease or inflammatory bowel disease.
    • EditedHistoryMajor gastrointestinal surgery within 3 months, excluding appendectomy or cholecystectomy; history of total colectomy or bariatric surgery.
    • RemovedConcurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy
    • EditedPatient diagnosedPrimary or secondary hyperparathyroidism. Any patient with a or PTH outside the range of 15 - 65 pg/ml will be excludedmL.
    • RemovedAll patients requiring pancreatic enzyme replacement will be excluded.
    • RemovedPatient with ongoing dialysis treatment
    • RemovedReceived chemotherapy treatment in the last 1 year
    • RemovedTreatment with antibiotics within 3 months of study entry. If subjects need to take antibiotics unexpectedly during the trial, they are excluded if they have already taken the fecal material transplant; if not, they can re-enroll in 3 months.
    • AddedPancreatic enzyme replacement, ongoing dialysis, or eGFR <60.
    • AddedChemotherapy in the prior year or concurrent intensive cancer therapy.
    • EditedRequiresAntibiotics within 3 months of study entry, continued antibiotic useneed, or anticipatesanticipated antibiotic use in the upcomingnext 4 weeks.
    • EditedPatients takingUnable to complete required washout from potassium citrate, thiazides, or proton pump inhibitors in the last 6 months.
    • RemovedWomen who are pregnant or breast-feeding or planning to get pregnant during the time of the study.
    • RemovedInability (e.g. dysphagia) to or unwilling to swallow capsules. Subjects with Grade greater than or equal to 2 dysphagia- as per Current Terminology for Common Adverse Events (CTCAE v 5.0) will be excluded.
    • RemovedActive gastrointestinal infection at time of enrollment
    • AddedPregnant, breastfeeding, or planning pregnancy during the study.
    • AddedUnable or unwilling to swallow capsules, including CTCAE grade >=2 dysphagia.
    • EditedKnown or suspectedActive gastrointestinal infection, toxic megacolon and/, or known small bowel ileus.

    …and 10 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 2 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedChangesChange in 24 -hour urinary oxalate concentration from baselineTime frame: Baseline to weeks 1, 3, and 5 → Baseline to Weeks 1, 3, and 5
    • EditedChangesChange in 24 -hour urinary calcium concentration from baselineTime frame: Baseline to week 1, 3, and 5 → Baseline to weeks 1, 3, and 5
    • Time frameProportion of participants with an adverse eventBaseline to day 30 (plus or minus 3 days) after fecal transplant → Through Day 30 (+/- 3 days) after MTT
    • DescriptionProportion of participants with an adverse event: how it is measured was reworded
    Secondary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedMetagenomic changes in participant microbiota before and after MTTTime frame: Baseline/pre-intervention through Week 5
    • RemovedMetagenomic changes to subject microbiota pre-MTTTime frame: Prior to fecal transplant (baseline)
    • RemovedMetagenomic changes to subject microbiota post-MTTTime frame: weeks 4 and 5 after MTT
    Interventions Changed Microbial Transplant Therapy→Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101). Added Drug: Vancomycin and neomycin antibiotic pretreatment; removed Drug: Placebo. Arms removed: Control group Hyperoxaluria·Control group Hypercalciuria
    Contact Study contact changed: d•••@imail.org · •••9421→n•••@imail.org · •••8280. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Park City Hospital · Park City, United StatesContact D•••@imail.org · •••9421→A•••@imail.org · •••9415
    + 7 other changes: verification date, oversight details, description, conditions, design details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05516472
Lead sponsor
Joshua Stern
Responsible party
Joshua Stern (Chief of Urology, Intermountain Health Care, Inc.) — Sponsor-investigator
First posted
Aug 25, 2022
Start date
Oct 10, 2024
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Nic Unsworth
Contact
nic.unsworth@imail.org
(801) 507-8280
Joshua Stern, MD
Contact
joshua.stern@imail.org
(435) 658-7400
Joshua Stern, MD
principal investigator · Intermountain Health Care, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion